Literature DB >> 21360269

Expression profile as predictor of relapse after adjuvant treatment in gastric cancer.

María Sereno1, Javier De Castro, Paloma Cejas, Miguel Angel García-Cabezas, Cristóbal Belda, Enrique Casado, Jaime Feliu, César Gómez, Miriam López, Manuel González Barón.   

Abstract

INTRODUCTION: TNM and histological subtype are the most important prognostic criteria in gastric cancer. In this study, we have tried to identify an immunohistochemical protein profile involved in gastric recurrence after a radical surgery.
MATERIALS AND METHODS: In this paper, protein panels involved in gastric carcinogenesis and progression was analyzed by immunohistochemistry expression: p53, Ki-67, Bcl-2, COX-2, c-erb-B2, EPO-R, E-cadherin, and β-catenin in 44 gastrectomy samples coming from gastrectomy pieces of patients diagnosed and operated on adenocarcinoma of the stomach followed by adjuvant treatment based on MacDonald chemoradiation regimen. An immunostaining profile that could predict the relapse after the end of adjuvant treatment was tried to find. These results have shown that the expression of the adverse prognostic protein profile based on positive p53 immunohistochemical expression and non-conserved E-cadherin/B-catenin staining is associated with tumor recurrence and a poor disease-free survival in operated gastric cancer patients with curative intent followed by adjuvant chemoradiation according to MacDonald's regimen. A protein profile based on immunohistochemical expression of p53 and E-cadherin-B-catenin that has a significant correlation to disease-free survival was identified in gastric cancer samples.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21360269     DOI: 10.1007/s12029-011-9267-z

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  24 in total

1.  Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses.

Authors:  S I Matsuzawa; J C Reed
Journal:  Mol Cell       Date:  2001-05       Impact factor: 17.970

2.  Mixed carcinoma of the stomach: a clinicopathological entity.

Authors:  F Carneiro; J C Machado; S Nabais; C M Santos; M Sobrinho Simões
Journal:  Histopathology       Date:  2003-07       Impact factor: 5.087

3.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION.

Authors:  P LAUREN
Journal:  Acta Pathol Microbiol Scand       Date:  1965

Review 4.  Histogenesis and biologic behavior of gastric carcinoma.

Authors:  R M Mulligan
Journal:  Pathol Annu       Date:  1972

5.  Amplification of the HER2 gene in breast cancers testing 2+ weak positive by HercepTest immunohistochemistry: false-positive or false-negative immunohistochemistry?

Authors:  Ciara Barrett; Hilary Magee; Denise O'Toole; Sinead Daly; Michael Jeffers
Journal:  J Clin Pathol       Date:  2006-07-05       Impact factor: 3.411

6.  Analysis of clinicopathologic prognostic features in patients with gastric adenocarcinoma.

Authors:  F Michelassi; D M Takanishi; D Pantalone; J Hart; R Chappell; G E Block
Journal:  Surgery       Date:  1994-10       Impact factor: 3.982

7.  Relationship between E-cadherin gene mutation and p53 gene mutation, p53 accumulation, Bcl-2 expression and Ki-67 staining in diffuse-type gastric carcinoma.

Authors:  Elena Fricke; Gisela Keller; Ingrid Becker; Erika Rosivatz; Christina Schott; Susanne Plaschke; Martina Rudelius; Christine Hermannstädter; Raymonde Busch; Heinz Höfler; Karl-Friedrich Becker; Birgit Luber
Journal:  Int J Cancer       Date:  2003-03-10       Impact factor: 7.396

8.  Increased incidence of undifferentiated type of gastric cancer with tumor progression in 912 patients with early gastric cancer and 1245 with advanced gastric cancer.

Authors:  Y Ikeda; M Mori; T Kamakura; Y Haraguchi; M Saku; K Sugimachi
Journal:  Cancer       Date:  1994-05-15       Impact factor: 6.860

9.  Expression profiling and subtype-specific expression of stomach cancer.

Authors:  Byungsik Kim; Seunghyun Bang; Seungkoo Lee; Soonok Kim; Yusun Jung; Changhee Lee; Kyungho Choi; Seong-Gene Lee; Kiwhan Lee; Yongsung Lee; Sang-Soo Kim; Yeong-Il Yeom; Yong-Sung Kim; Hyang-Sook Yoo; Kyuyoung Song; Inchul Lee
Journal:  Cancer Res       Date:  2003-12-01       Impact factor: 12.701

10.  p53 status and the efficacy of cancer therapy in vivo.

Authors:  S W Lowe; S Bodis; A McClatchey; L Remington; H E Ruley; D E Fisher; D E Housman; T Jacks
Journal:  Science       Date:  1994-11-04       Impact factor: 47.728

View more
  2 in total

Review 1.  Abnormal β-catenin immunohistochemical expression as a prognostic factor in gastric cancer: a meta-analysis.

Authors:  Li-Fu Li; Zheng-Jie Wei; Hong Sun; Bo Jiang
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

2.  The expression of Bcl-2 and BID in gastric cancer cells.

Authors:  Mariusz Gryko; Anna Pryczynicz; Konrad Zareba; Bogusław Kędra; Andrzej Kemona; Katarzyna Guzińska-Ustymowicz
Journal:  J Immunol Res       Date:  2014-02-19       Impact factor: 4.818

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.